{"relationship_key":"C0001403:SUBTYPE_OF:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":153,"text_span":"The most common cause of primary adrenal insufficiency is autoimmunity; this type is often called Autoimmune Addison's Disease, or simply autoimmune PAI.","confidence":0.95,"supports":true}
{"relationship_key":"C0004358:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":129,"text_span":"In Western countries, where other than autoimmune causes of PAI are uncommon, serum 21-hydroxylase antibodies should be assessed.","confidence":0.9,"supports":true}
{"relationship_key":"C0004358:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":236,"text_span":"These antibodies have since then been shown to be highly specific for autoimmune PAI in several patient cohorts, and found present in 80–90% of patients with PAI in cross-sectional studies after exclusion of known non-autoimmune causes.","confidence":0.95,"supports":true}
{"relationship_key":"C0020268:TREATS:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":136,"text_span":"The standard medication of glucocorticoid treatment for patients with AI (primary and secondary) is hydrocortisone or cortisone acetate.","confidence":0.9,"supports":true}
{"relationship_key":"C0010137:TREATS:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":136,"text_span":"The standard medication of glucocorticoid treatment for patients with AI (primary and secondary) is hydrocortisone or cortisone acetate.","confidence":0.9,"supports":true}
{"relationship_key":"C0016314:TREATS:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":102,"text_span":"Patients with primary AI additionally take fludrocortisone treatment for mineralocorticoid deficiency.","confidence":0.9,"supports":true}
{"relationship_key":"C0201517:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":127,"text_span":"A healthy person is expected to have >500 nmol/L of plasma cortisol concentration 60 minutes after 250µg cosyntropin injection.","confidence":0.9,"supports":true}
{"relationship_key":"C0020268:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":126,"text_span":"Morning cortisol concentration <140 nmol/L and an ACTH concentration twice the upper reference limit verifies a PAI diagnosis.","confidence":0.9,"supports":true}
{"relationship_key":"C0001655:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":126,"text_span":"Morning cortisol concentration <140 nmol/L and an ACTH concentration twice the upper reference limit verifies a PAI diagnosis.","confidence":0.9,"supports":true}
{"relationship_key":"C1413642:ASSOCIATED_WITH:C0001627","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":197,"text_span":"Skov and collaborators recently showed, by analyzing 29 twin pairs with PAI, a concordance for monozygotic twins of 0.71 and a heritability of 0.97, revealing that PAI is a highly genetic disorder.","confidence":0.95,"supports":true}
{"relationship_key":"C1413642:ASSOCIATED_WITH:C0085859","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":197,"text_span":"Skov and collaborators recently showed, by analyzing 29 twin pairs with PAI, a concordance for monozygotic twins of 0.71 and a heritability of 0.97, revealing that PAI is a highly genetic disorder.","confidence":0.95,"supports":true}
{"relationship_key":"C0038462:ASSOCIATED_WITH:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":135,"text_span":"The autoantibodies targeting 21-OH was first described in 1992 by Winqvist et al., identified as a major autoantigen in autoimmune PAI.","confidence":0.9,"supports":true}
{"relationship_key":"C0162834:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":126,"text_span":"Morning cortisol concentration <140 nmol/L and an ACTH concentration twice the upper reference limit verifies a PAI diagnosis.","confidence":0.9,"supports":true}
{"relationship_key":"C1262477:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":126,"text_span":"Morning cortisol concentration <140 nmol/L and an ACTH concentration twice the upper reference limit verifies a PAI diagnosis.","confidence":0.9,"supports":true}
{"relationship_key":"C0015672:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":126,"text_span":"Morning cortisol concentration <140 nmol/L and an ACTH concentration twice the upper reference limit verifies a PAI diagnosis.","confidence":0.9,"supports":true}
{"relationship_key":"C0001403:ASSOCIATED_WITH:C0085859","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":136,"text_span":"There are several underlying causes for adrenal insufficiency, where an autoimmune attack by the immune system is the most common cause.","confidence":0.9,"supports":true}
{"relationship_key":"C0001403:ASSOCIATED_WITH:C0011854","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":129,"text_span":"In Western countries, where other than autoimmune causes of PAI are uncommon, serum 21-hydroxylase antibodies should be assessed.","confidence":0.9,"supports":true}
{"relationship_key":"C0001403:ASSOCIATED_WITH:C0040128","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":129,"text_span":"In Western countries, where other than autoimmune causes of PAI are uncommon, serum 21-hydroxylase antibodies should be assessed.","confidence":0.9,"supports":true}
{"relationship_key":"C0001403:ASSOCIATED_WITH:C0007570","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":129,"text_span":"In Western countries, where other than autoimmune causes of PAI are uncommon, serum 21-hydroxylase antibodies should be assessed.","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:INDICATES:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":133,"text_span":"Desmopressin is increasingly used for the diagnosis of Cushing disease (CD) since corticotropin-releasing hormone became unavailable.","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:ASSOCIATED_WITH:C0001655","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":78,"text_span":"Intravenous desmopressin administration produced no ACTH or cortisol increase.","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:ASSOCIATED_WITH:C0001655","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":190,"text_span":"Inferior petrosal sinus sampling (IPSS) with desmopressin stimulation resulted in elevated central-to-peripheral ACTH ratio and prolactin co-secretion, while peripheral ACTH remained stable.","confidence":0.9,"supports":true}
{"relationship_key":"C0107870:INCREASES_RISK:C0001403","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":113,"text_span":"Cabergoline was initiated, after which the patient rapidly developed transient severe adrenal insufficiency (AI).","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:ASSOCIATED_WITH:C1336641","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"The mechanism by which desmopressin stimulates ACTH secretion in CD may result from overexpression of AVPR1B receptors as well as ectopic AVPR2 receptors in corticotroph adenomas, which is more prevalent in tumors harboring USP8 mutations.","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:ASSOCIATED_WITH:C1336642","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"The mechanism by which desmopressin stimulates ACTH secretion in CD may result from overexpression of AVPR1B receptors as well as ectopic AVPR2 receptors in corticotroph adenomas, which is more prevalent in tumors harboring USP8 mutations.","confidence":0.9,"supports":true}
{"relationship_key":"C1336641:ASSOCIATED_WITH:C0001430","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"The mechanism by which desmopressin stimulates ACTH secretion in CD may result from overexpression of AVPR1B receptors as well as ectopic AVPR2 receptors in corticotroph adenomas, which is more prevalent in tumors harboring USP8 mutations.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0011847","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":135,"text_span":"Over the previous 2 years he had developed diabetes, hypertension, hypokalemia, osteoporosis, obesity, and overt Cushingoid appearance.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0020538","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":135,"text_span":"Over the previous 2 years he had developed diabetes, hypertension, hypokalemia, osteoporosis, obesity, and overt Cushingoid appearance.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0020621","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":135,"text_span":"Over the previous 2 years he had developed diabetes, hypertension, hypokalemia, osteoporosis, obesity, and overt Cushingoid appearance.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0029456","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":135,"text_span":"Over the previous 2 years he had developed diabetes, hypertension, hypokalemia, osteoporosis, obesity, and overt Cushingoid appearance.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0028754","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":135,"text_span":"Over the previous 2 years he had developed diabetes, hypertension, hypokalemia, osteoporosis, obesity, and overt Cushingoid appearance.","confidence":0.9,"supports":true}
{"relationship_key":"canon-948f522bafc7:INDICATES:C0020268","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":103,"text_span":"However, pathology showed normal pituitary tissue with rare Crooke's cells, suggesting cortisol excess.","confidence":0.9,"supports":true}
{"relationship_key":"C0020268:TREATS:C0001403","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":111,"text_span":"AI was diagnosed, and the patient's condition promptly resolved with IV hydrocortisone and fluid resuscitation.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:CAUSED_BY:C0032000","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"Rates of recurrence and/or persistence of Cushing's disease after surgical treatment are high","confidence":0.9,"supports":true}
{"relationship_key":"C0087111:TREATS:C0221406","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":137,"text_span":"transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for this disease, up to one-third of the patients eventually relapse","confidence":0.9,"supports":true}
{"relationship_key":"C1871526:TREATS:C0221406","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":198,"text_span":"The first randomized phase III clinical trial involving 162 patients with CD treated with subcutaneous pasireotide showed urine-free cortisol (UFC) normalization at month 6 in 15–26% of the patients","confidence":0.9,"supports":true}
{"relationship_key":"C4308655:TREATS:C0221406","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":101,"text_span":"levoketoconazole normalized mean urinary free cortisol (mUFC) levels in more than 50% of the patients","confidence":0.9,"supports":true}
{"relationship_key":"C3852966:TREATS:C0221406","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":129,"text_span":"osilodrostat resulted in a complete response in 66% and a partial response (≥50% reduction of UFC) in 9% of the enrolled patients","confidence":0.9,"supports":true}
{"relationship_key":"C4308656:TREATS:C0221406","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":162,"text_span":"42% and 15% of the patients coming from the low-dose group (200 mg/day) demonstrated a blood pressure reduction of ≥5 mmHg and a glycaemic reduction, respectively","confidence":0.9,"supports":true}
{"relationship_key":"C1871526:TARGETS:C0288267","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":144,"text_span":"ACTH-secreting tumours express somatostatin receptor 2 (SSTR2) and SSTR5 messenger RNAs (mRNAs) (>85%) and, to a lesser degree, SSTR1 mRNA (63%)","confidence":0.9,"supports":true}
{"relationship_key":"C1336641:ASSOCIATED_WITH:C0001430","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"36–62% of corticotroph adenomas show gain-of-function mutations in the gene encoding for USP8","confidence":0.9,"supports":true}
{"relationship_key":"canon-f4c38c837daa:ASSOCIATED_WITH:C0032000","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":215,"text_span":"The study by Pekul et al. emphasized the relevance of USP and TP53 mutations in pituitary tumors for prognostic guidance by comparing corticotroph tumors causing Cushing's disease (CD) with their silent counterparts","confidence":0.9,"supports":true}
{"relationship_key":"C0079419:ASSOCIATED_WITH:C0032000","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":215,"text_span":"The study by Pekul et al. emphasized the relevance of USP and TP53 mutations in pituitary tumors for prognostic guidance by comparing corticotroph tumors causing Cushing's disease (CD) with their silent counterparts","confidence":0.9,"supports":true}
{"relationship_key":"C0001622:ASSOCIATED_WITH:C0221406","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":215,"text_span":"The study by Pekul et al. emphasized the relevance of USP and TP53 mutations in pituitary tumors for prognostic guidance by comparing corticotroph tumors causing Cushing's disease (CD) with their silent counterparts","confidence":0.9,"supports":true}
{"relationship_key":"C0011701:INDICATES:canon-2193e082baff","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":189,"text_span":"A meta-analysis by Giampetro et al. evaluated the use of desmopressin for diagnostic purposes, a review that is particularly relevant given the limited availability of CRH in many countries","confidence":0.9,"supports":true}
{"relationship_key":"C1871526:TREATS:C0221406","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":136,"text_span":"The study demonstrated that this combination of pituitary-targeted therapies can yield sustained long-term efficacy in selected patients","confidence":0.9,"supports":true}
{"relationship_key":"C0107870:TREATS:C0221406","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":136,"text_span":"The study demonstrated that this combination of pituitary-targeted therapies can yield sustained long-term efficacy in selected patients","confidence":0.9,"supports":true}
{"relationship_key":"C0020626:ASSOCIATED_WITH:C3887843","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":136,"text_span":"The study demonstrated that this combination of pituitary-targeted therapies can yield sustained long-term efficacy in selected patients","confidence":0.9,"supports":true}
{"relationship_key":"C0031511:CAUSES:C0342482","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":152,"text_span":"Histopathological examination confirmed a pheochromocytoma; however, both anti-ACTH and anti-CRH stainings were negative, leading to a diagnosis of PCS.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0020626","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0025598","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0020626","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":338,"text_span":"The patient underwent adrenalectomy following pre-treatment with doxazosin and metyrapone, enteral feeding, protein supplementation, and insulin administration. Post-surgery, the patient did not require further antidiabetic medication, experienced gradual weight gain, improved well-being, and did not need glucocorticoid supplementation.","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0020626","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":321,"text_span":"A rapid decrease in the level of cortisol, ACTH, and metanephrines upon initiation of metyrapone treatment suggests the existence of a glucocorticoid-dependent positive feedback loop that potentiated ACTH release and created a destructive cycle with rapid exacerbation of both hypercortisolemia and hypercatecholaminemia.","confidence":0.9,"supports":true}
{"relationship_key":"C0007412:CAUSES:C0020624","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":191,"text_span":"In this case, we hypothesize that abundant and chronic secretion of catecholamines from the tumor led to a hypermetabolic and pro-inflammatory state that, in turn, overactivated the HPA axis.","confidence":0.9,"supports":true}
{"relationship_key":"C0020624:ACTIVATES:C0597719","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":191,"text_span":"In this case, we hypothesize that abundant and chronic secretion of catecholamines from the tumor led to a hypermetabolic and pro-inflammatory state that, in turn, overactivated the HPA axis.","confidence":0.9,"supports":true}
{"relationship_key":"C0032000:CAUSES:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":164,"text_span":"Cushing's disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma and is the most common cause of endogenous Cushing's syndrome.","confidence":0.95,"supports":true}
{"relationship_key":"6135:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":221,"text_span":"The median percentage of patients with CD receiving medical treatment was 13.3% (4.8–82.9). Ketoconazole was the most frequently used drug, with a median rate of usage of 26.5% (5-66.7) of those receiving medical therapy.","confidence":0.95,"supports":true}
{"relationship_key":"6135:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":98,"text_span":"The median biochemical control rate of ketoconazole provided by 7 centers was 76% (range: 20–100).","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":147,"text_span":"Biochemical control rates with pasireotide and metyrapone, available from 5 centers, were 80% (range: 50–100) and 60% (range: 10–80), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"1234567:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":147,"text_span":"Biochemical control rates with pasireotide and metyrapone, available from 5 centers, were 80% (range: 50–100) and 60% (range: 10–80), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"2049836:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":161,"text_span":"The rate of biochemical control with osilodrostat and combination therapy provided by 4 centers were 65% (range: 33–100) and 73.8% (range: 50–100), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"canon-b6653513916a:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":161,"text_span":"The rate of biochemical control with osilodrostat and combination therapy provided by 4 centers were 65% (range: 33–100) and 73.8% (range: 50–100), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0087111:TREATS:C0221406","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":251,"text_span":"The recommended first-line therapy is selective transsphenoidal surgical resection of the ACTH-secreting adenoma. Remission rates after surgery are dependent on surgeon expertise and may reach 83% for microadenomas and 68% for macroadenomas in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"6135:SUBTYPE_OF:canon-b89aba72e36c","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":205,"text_span":"Adrenal steroidogenesis inhibitors were the most commonly used medications amongst the centers. Despite the use of combination therapy, up to 25% of patients did not achieve disease control even in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"6876:SUBTYPE_OF:canon-b89aba72e36c","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":205,"text_span":"Adrenal steroidogenesis inhibitors were the most commonly used medications amongst the centers. Despite the use of combination therapy, up to 25% of patients did not achieve disease control even in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"2049836:SUBTYPE_OF:canon-b89aba72e36c","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":205,"text_span":"Adrenal steroidogenesis inhibitors were the most commonly used medications amongst the centers. Despite the use of combination therapy, up to 25% of patients did not achieve disease control even in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"1234567:SUBTYPE_OF:canon-019648ee0a5e","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":251,"text_span":"The recommended first-line therapy is selective transsphenoidal surgical resection of the ACTH-secreting adenoma. Remission rates after surgery are dependent on surgeon expertise and may reach 83% for microadenomas and 68% for macroadenomas in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"6585:SUBTYPE_OF:canon-ab60166dfd1e","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":251,"text_span":"The recommended first-line therapy is selective transsphenoidal surgical resection of the ACTH-secreting adenoma. Remission rates after surgery are dependent on surgeon expertise and may reach 83% for microadenomas and 68% for macroadenomas in PTCOEs.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f8209405928c:CAUSED_BY:canon-d812f0c1a1fa","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":251,"text_span":"The genetic cause of CAH-X syndrome is a recombination event between TNXB and its pseudogene TNXA. The resulting 30 kb deletion includes the entire CYP21A2 gene sequence and part of the TNXB gene and produces a chimeric TNXA/TNXB gene (CAH-X chimera).","confidence":0.95,"supports":true}
{"relationship_key":"4603:TREATS:C0342482","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":317,"text_span":"The main therapies in CAH are glucocorticoids to replace the deficiency and normalize the adrenal androgens and mineralocorticoids, compulsory in SW CAH but often also used in SV CAH. Mineralocorticoids, in the form of fludrocortisone, are particularly important prior to and during pregnancy in patients with SW CAH.","confidence":0.95,"supports":true}
{"relationship_key":"canon-839d4bd2623b:ASSOCIATED_WITH:C1291311","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":253,"text_span":"Over 95% of deleterious variants leading to 21OHD are attributable to intergenic recombination events where microconversions, consisting in the transfer to CYP21A2 of deleterious variants usually present in the CYP21A1P pseudogene, represent 70% to 75%.","confidence":0.95,"supports":true}
{"relationship_key":"canon-bc7a9cf7640b:ASSOCIATED_WITH:C0342483","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":253,"text_span":"Over 95% of deleterious variants leading to 21OHD are attributable to intergenic recombination events where microconversions, consisting in the transfer to CYP21A2 of deleterious variants usually present in the CYP21A1P pseudogene, represent 70% to 75%.","confidence":0.95,"supports":true}
{"relationship_key":"canon-361a9c15e5e7:ASSOCIATED_WITH:C0342482","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":253,"text_span":"Over 95% of deleterious variants leading to 21OHD are attributable to intergenic recombination events where microconversions, consisting in the transfer to CYP21A2 of deleterious variants usually present in the CYP21A1P pseudogene, represent 70% to 75%.","confidence":0.95,"supports":true}
{"relationship_key":"canon-6efadc4f582f:INCREASES_RISK:canon-b1324cb406d8","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":258,"text_span":"High cortisol exerts its effects through glucocorticoid receptors and mineralocorticoid receptors in the hippocampus, mediating neurophysiological responses. Prolonged activation may lead to neuronal damage, reduced neuroplasticity, and cognitive impairment.","confidence":0.9,"supports":true}
{"relationship_key":"canon-6efadc4f582f:INCREASES_RISK:canon-e2d9031797de","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":258,"text_span":"High cortisol exerts its effects through glucocorticoid receptors and mineralocorticoid receptors in the hippocampus, mediating neurophysiological responses. Prolonged activation may lead to neuronal damage, reduced neuroplasticity, and cognitive impairment.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ef935eaabf01:INCREASES_RISK:C4023662","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":174,"text_span":"Circadian rhythm disruption may accelerate hippocampal atrophy and prefrontal cortex dysfunction by affecting the regulation of the hypothalamic-pituitary-adrenal (HPA) axis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ef935eaabf01:INCREASES_RISK:C0162783","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":174,"text_span":"Circadian rhythm disruption may accelerate hippocampal atrophy and prefrontal cortex dysfunction by affecting the regulation of the hypothalamic-pituitary-adrenal (HPA) axis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ef935eaabf01:ASSOCIATED_WITH:C0597719","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":174,"text_span":"Circadian rhythm disruption may accelerate hippocampal atrophy and prefrontal cortex dysfunction by affecting the regulation of the hypothalamic-pituitary-adrenal (HPA) axis.","confidence":0.9,"supports":true}
{"relationship_key":"C3852966:TREATS:canon-1f8884d825b8","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":97,"text_span":"Osilodrostat is a new drug approved for the treatment of adults with endogenous Cushing syndrome.","confidence":0.95,"supports":true}
{"relationship_key":"C3852966:INHIBITS:C0010751","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":127,"text_span":"Osilodrostat is a potent inhibitor of 11-beta-hydroxylase, an enzyme that catalyses cortisol biosynthesis in the adrenal gland.","confidence":0.95,"supports":true}
{"relationship_key":"C0010751:CATALYZES:canon-2ea9a190518d","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":127,"text_span":"Osilodrostat is a potent inhibitor of 11-beta-hydroxylase, an enzyme that catalyses cortisol biosynthesis in the adrenal gland.","confidence":0.95,"supports":true}
{"relationship_key":"C3852966:INCREASES_RISK:C0001623","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":172,"text_span":"Hypocortisolism-related adverse events (mostly reported as adrenal insufficiency or glucocorticoid deficiency) occurred in 70/138 (51%) of patients across the entire study.","confidence":0.95,"supports":true}
{"relationship_key":"C3852966:INCREASES_RISK:canon-a0ee87e8dec5","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":127,"text_span":"A decrease in serum potassium concentration was observed in some patients, with 7 (5%) patients developing severe hypokalaemia.","confidence":0.95,"supports":true}
{"relationship_key":"C3852966:INCREASES_RISK:canon-6ae5d10a9469","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":57,"text_span":"QT interval prolongation was reported in 5 (4%) patients.","confidence":0.95,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0017710","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-0c98a1fe94db:INDICATES:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":145,"text_span":"We developed a linear mathematical model with high predictive ability, achieving a classification accuracy of 97.03% and a Kappa value of 94.05%.","confidence":0.95,"supports":true}
{"relationship_key":"C0011777:INDICATES:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"canon-736331ab2e73:INDICATES:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"canon-f88ec8b79c32:INDICATES:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"canon-390adc708a33:SUBTYPE_OF:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-c827c37cac43:SUBTYPE_OF:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-531c313092e3:SUBTYPE_OF:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"C3495587:SUBTYPE_OF:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"C0011777:TREATS:C0221406","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:ASSOCIATED_WITH:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":169,"text_span":"ST3Gal1 expression was found to be associated with inflammation of the intestinal mucosa in patients with UC and a mouse model of dextran sulfate sodium-induced colitis.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:ASSOCIATED_WITH:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":154,"text_span":"The mRNA expression levels of ST3Gal1 in the mucosal tissue of individuals diagnosed with UC were significantly higher than those in healthy colon mucosa.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:C3178854","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":213,"text_span":"Suppressed expression of ST3Gal1 in the intestinal epithelial cell (IEC) monolayer enhanced the functionality of the intestinal barrier, whereas its overexpression caused intestinal barrier function deterioration.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:C3178854","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":145,"text_span":"The TEER levels in the ST3Gal1-sh3/IEC group were significantly higher than those in the IEC and sh-Ctr/IEC groups after stimulation with 2% DSS.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:7512","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:7512","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":187,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11757","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11757","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":187,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:1806","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:1806","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":187,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11364","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11364","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":187,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":135,"text_span":"Knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":135,"text_span":"Knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":318,"text_span":"ST3Gal1 expression in the IEC monolayer altered the expression of intestinal mucus barrier-associated mucin 2 (MUC2) and trefoil factor 3 (TFF3), goblet cell differentiation-associated homeobox protein CDX-2 (CDX2), inflammation-associated phosphorylated (p)-STAT3, and the inflammatory mediators IL-1β, IL-6 and IL-8.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":135,"text_span":"Knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer.","confidence":0.95,"supports":true}
{"relationship_key":"canon-06ef233adacb:ASSOCIATED_WITH:C3178854","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":213,"text_span":"Suppressed expression of ST3Gal1 in the intestinal epithelial cell (IEC) monolayer enhanced the functionality of the intestinal barrier, whereas its overexpression caused intestinal barrier function deterioration.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:REGULATES:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":183,"text_span":"Transfection of shRNA vectors targeting PTBP1 effectively reduced PTBP1 expression in Ishikawa and KLE cell lines and substantially inhibited cell viability in these two EC cell lines","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:REGULATES:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":168,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions in Ishikawa and KLE cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:BINDS_TO:HGNC:11059","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":168,"text_span":"The fold enrichment of SLC7A11 mRNA in anti-PTBP1 immunoprecipitations, compared to anti-IgG controls, revealed approximately a four-fold increase in SLC7A11 enrichment","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:REGULATES:canon-8f7fec5b0ebb","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":79,"text_span":"The half-life of SLC7A11 mRNA was significantly shortened upon PTBP1 disruption","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11059:REGULATES:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":169,"text_span":"Co-transfection with an SLC7A11 ORF plasmid significantly increased SLC7A11 protein levels in PTBP1-depleted cells and partially but significantly rescued cell viability","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16848:INCREASES_RISK:C0024623","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":159,"text_span":"YY1 was highly expressed in gastric cancer tissues and cells. Kaplan-Meier survival curves indicated that high YY1 expression correlated with a poor prognosis.","confidence":0.95,"supports":true}
{"relationship_key":"canon-136ba3ca8e29:INCREASES_RISK:C0024623","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":101,"text_span":"YY1 expression showed a gradually increasing trend in H. pylori-induced gastritis and gastric tumors.","confidence":0.9,"supports":true}
{"relationship_key":"canon-136ba3ca8e29:INCREASES_RISK:C0024623","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":182,"text_span":"In vivo and in vitro experiments demonstrated that H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.95,"supports":true}
{"relationship_key":"canon-136ba3ca8e29:INCREASES:HGNC:16848","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":101,"text_span":"YY1 expression showed a gradually increasing trend in H. pylori-induced gastritis and gastric tumors.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:ACTIVATES:canon-ad46585bfe4d","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":182,"text_span":"In vivo and in vitro experiments demonstrated that H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16848:ACTIVATES:canon-ad46585bfe4d","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":72,"text_span":"YY1 and JAK2 interaction was validated by chromatin immunoprecipitation.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:C1523298","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":182,"text_span":"In vivo and in vitro experiments demonstrated that H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:C1523298","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ad46585bfe4d:PROMOTES:C1523298","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":182,"text_span":"In vivo and in vitro experiments demonstrated that H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.95,"supports":true}
{"relationship_key":"C1523298:PROMOTES:C0024623","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":182,"text_span":"In vivo and in vitro experiments demonstrated that H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.95,"supports":true}
{"relationship_key":"C0389995:TREATS:C0024623","document_id":"PMC11362397","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":223,"text_span":"PSMD14 demonstrates elevated mRNA expression across multiple cancer types compared to normal tissues. In lung adenocarcinoma (LUAD), PSMD14 is upregulated not only at the transcriptional level but also at the protein level.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INDICATES:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":223,"text_span":"PSMD14 exhibits significant diagnostic value in LUAD. Receiver operating characteristic (ROC) curve analysis yielded an area under the curve (AUC) of 0.898 (95% CI: 0.877–0.918), suggesting excellent diagnostic performance.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:C4086681","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:canon-0f64ef24def0","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:canon-27ab61c53094","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:canon-3b789a496ebd","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INTERACTS_WITH:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":158,"text_span":"PSMD14 knockdown markedly enhanced HMMR ubiquitination, whereas its overexpression reduced it. PSMD14 primarily cleaved K63-linked ubiquitin chains from HMMR.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:canon-50c00bfc1843","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":158,"text_span":"PSMD14 knockdown markedly enhanced HMMR ubiquitination, whereas its overexpression reduced it. PSMD14 primarily cleaved K63-linked ubiquitin chains from HMMR.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:canon-91d5cb4a32cd","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":285,"text_span":"PSMD14 knockdown led to reduced expression of TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:canon-53bbeef07361","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":285,"text_span":"PSMD14 knockdown led to reduced expression of TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"canon-1e7a2025e674:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"C3852671:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"C0149925:SUBTYPE_OF:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":190,"text_span":"Despite the integration of PD-L1 inhibitors with chemotherapy, extensive-stage small-cell lung cancer (ES-SCLC) continues to portend a dismal prognosis, with a 5-year survival rate below 10%","confidence":0.95,"supports":true}
{"relationship_key":"canon-4faf4acb27cd:INDICATES:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"canon-4faf4acb27cd:INDICATES:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":146,"text_span":"The DDR-IF score was defined using standardized coefficients: DDR-IF = 0.4 × (HRD score) + 0.35 × log10(TMB + 1) + 0.25 × (STING activation score)","confidence":0.95,"supports":true}
{"relationship_key":"C2316164:TREATS:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"C2316164:TREATS:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"C4055433:TREATS:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"C4055433:TREATS:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"canon-4faf4acb27cd:ASSOCIATED_WITH:canon-8d08a5ffda11","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"canon-4faf4acb27cd:ASSOCIATED_WITH:canon-8d08a5ffda11","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"canon-0b4ee459bd3a:ASSOCIATED_WITH:C0919532","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":146,"text_span":"The DDR-IF score was defined using standardized coefficients: DDR-IF = 0.4 × (HRD score) + 0.35 × log10(TMB + 1) + 0.25 × (STING activation score)","confidence":0.95,"supports":true}
{"relationship_key":"canon-72697c0dca11:ASSOCIATED_WITH:C0919532","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":146,"text_span":"The DDR-IF score was defined using standardized coefficients: DDR-IF = 0.4 × (HRD score) + 0.35 × log10(TMB + 1) + 0.25 × (STING activation score)","confidence":0.95,"supports":true}
{"relationship_key":"canon-67edbc53a1d4:ASSOCIATED_WITH:canon-e8ae090bf285","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"canon-26b838174e83:ASSOCIATED_WITH:C0012899","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"C0376571:ASSOCIATED_WITH:C0012899","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"C0376571:ASSOCIATED_WITH:C0012899","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":183,"text_span":"A meta-analysis of six trials (2020–2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% vs. 18%, p=0.003)","confidence":0.9,"supports":true}
{"relationship_key":"canon-a381d63fc49c:TREATS:C0149925","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":201,"text_span":"In the SCLC-specific phase Ib trial NCT04564027, the RAD51 inhibitor CYT-0851 achieved a 38% disease control rate, with matched biopsies revealing a STING-dependent 6.8-fold increase in CXCL10 (p=0.02)","confidence":0.9,"supports":true}
{"relationship_key":"C0242629:ASSOCIATED_WITH:C1956108","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":379,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003)","confidence":0.95,"supports":true}
{"relationship_key":"canon-32b197e63452:ASSOCIATED_WITH:C2316164","document_id":"PMC12757875","section":null,"start_offset":0,"end_offset":201,"text_span":"In the SCLC-specific phase Ib trial NCT04564027, the RAD51 inhibitor CYT-0851 achieved a 38% disease control rate, with matched biopsies revealing a STING-dependent 6.8-fold increase in CXCL10 (p=0.02)","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":147,"text_span":"Breast cancer remains the most common cancer globally, with approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":147,"text_span":"Breast cancer remains the most common cancer globally, with approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2.","confidence":0.95,"supports":true}
{"relationship_key":"canon-31f285d80775:ASSOCIATED_WITH:C0476089","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":236,"text_span":"HRD subtyping identified distinct genomic, pathological, and immunological features. HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration.","confidence":0.95,"supports":true}
{"relationship_key":"canon-c3020b2ac938:INDICATES:canon-9f310f9fb687","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":163,"text_span":"HRD subtyping independently predicted disease-free survival and showed superior prognostic accuracy (C-index = 0.857) compared to TCGA subtyping (C-index = 0.751).","confidence":0.95,"supports":true}
{"relationship_key":"canon-c3020b2ac938:COMPOSED_OF:C0024880","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":100,"text_span":"The HRD score was calculated as the arithmetic sum of three genomic scar metrics: LOH, TAI, and LST.","confidence":0.95,"supports":true}
{"relationship_key":"canon-c3020b2ac938:COMPOSED_OF:canon-b30617cc3023","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":100,"text_span":"The HRD score was calculated as the arithmetic sum of three genomic scar metrics: LOH, TAI, and LST.","confidence":0.95,"supports":true}
{"relationship_key":"canon-c3020b2ac938:COMPOSED_OF:canon-8af811b2051d","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":100,"text_span":"The HRD score was calculated as the arithmetic sum of three genomic scar metrics: LOH, TAI, and LST.","confidence":0.95,"supports":true}
{"relationship_key":"canon-31f285d80775:ASSOCIATED_WITH:HGNC:11998","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":236,"text_span":"HRD subtyping identified distinct genomic, pathological, and immunological features. HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration.","confidence":0.95,"supports":true}
{"relationship_key":"canon-31f285d80775:ASSOCIATED_WITH:canon-8599d87dd557","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":236,"text_span":"HRD subtyping identified distinct genomic, pathological, and immunological features. HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration.","confidence":0.95,"supports":true}
{"relationship_key":"canon-31f285d80775:ASSOCIATED_WITH:canon-feafad79f419","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":236,"text_span":"HRD subtyping identified distinct genomic, pathological, and immunological features. HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration.","confidence":0.95,"supports":true}
{"relationship_key":"canon-38b09b8c15c5:INDICATES:canon-9f310f9fb687","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":163,"text_span":"HRD subtyping independently predicted disease-free survival and showed superior prognostic accuracy (C-index = 0.857) compared to TCGA subtyping (C-index = 0.751).","confidence":0.95,"supports":true}
{"relationship_key":"canon-90b9d329abc1:PREDICTS:C0476089","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":108,"text_span":"An SVM model incorporating HRD score and immune features achieved an AUC of 0.733 for recurrence prediction.","confidence":0.95,"supports":true}
{"relationship_key":"canon-7cb98cd143aa:ASSOCIATED_WITH:C0281477","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"canon-7cb98cd143aa:STUDIED_IN:canon-f902b4941488","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":116,"text_span":"A web-based cross-sectional study was conducted between June and July 2023 across two medical universities in China.","confidence":0.95,"supports":true}
{"relationship_key":"canon-7cb98cd143aa:STUDIED_IN:canon-f902b4941488","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":115,"text_span":"A total of 520 valid questionnaires were collected, with 304 (58.46%) females and a mean age of 21.07 ± 2.25 years.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f2deda17ed1a:INDICATES:canon-7cb98cd143aa","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":277,"text_span":"Structural equation modeling (SEM) indicated that knowledge directly influenced attitude (β = 0.140, P = 0.003), attitude directly affected practice (β = 0.145, P = 0.002), and knowledge had a substantial and direct impact on practice impact on practice (β = 0.219, P < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-26cc63822a57:INDICATES:canon-7cb98cd143aa","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":187,"text_span":"Correlation analysis demonstrated significant positive correlations between knowledge and practice (r = 0.230, P < 0.001), as well as between attitude and practice (r = 0.136, P = 0.002).","confidence":0.95,"supports":true}
{"relationship_key":"C0242379:SCREENED_BY:C1531652","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C1527249:SCREENED_BY:C0009378","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C1527249:SCREENED_BY:C1531728","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0345904:SCREENED_BY:C0203446","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0345904:SCREENED_BY:C0002210","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0238033:SCREENED_BY:C0024671","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0238033:SCREENED_BY:C0203446","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0007847:SCREENED_BY:canon-1c0f27366769","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0024623:SCREENED_BY:canon-3ec89212f61e","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0024623:SCREENED_BY:C0017150","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0024623:SCREENED_BY:canon-f06f5635fa79","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"C0024623:SCREENED_BY:C0017195","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"canon-68302d7e5890:ASSOCIATED_WITH:canon-a1a35ba8c9ab","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-68302d7e5890:NOT_ASSOCIATED_WITH:canon-256e1dd5dcfd","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-68302d7e5890:NOT_ASSOCIATED_WITH:C0038954","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-68302d7e5890:NOT_ASSOCIATED_WITH:canon-2237698ea3dd","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-68302d7e5890:NOT_ASSOCIATED_WITH:canon-4ce7d75205f8","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-3ae797e3a88e:NOT_ASSOCIATED_WITH:canon-7f7d10d777fc","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":105,"text_span":"Meanwhile, few significant disparities in healthcare utilization between Han and Mongolian were observed.","confidence":0.95,"supports":true}
{"relationship_key":"canon-60c7925fbe56:INCREASES_RISK:canon-4ce7d75205f8","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":201,"text_span":"After adjusted for covariates, male breast cancer patients residing in cities of a low GDP level were associated with increased breast-cancer specific mortality (HR, 22.5, [95% CI: 1.6–325.0]; P=0.022)","confidence":0.95,"supports":true}
{"relationship_key":"canon-16adbc4d267a:INDICATES:canon-a75e1d47d59c","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce0723b35156:INDICATES:canon-a75e1d47d59c","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-16adbc4d267a:INDICATES:canon-3bf1715d5aaf","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-16adbc4d267a:INDICATES:canon-3bf1715d5aaf","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":361,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of NTRK and FGFR fusions, two cases each of BRAF, RAF1, and ALK fusions, and one case each of RET, ROS1, and EGFR fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (p = 0.019).","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce0723b35156:INDICATES:canon-3bf1715d5aaf","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce0723b35156:INDICATES:canon-3bf1715d5aaf","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":361,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of NTRK and FGFR fusions, two cases each of BRAF, RAF1, and ALK fusions, and one case each of RET, ROS1, and EGFR fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (p = 0.019).","confidence":0.95,"supports":true}
{"relationship_key":"canon-16adbc4d267a:INDICATES:canon-51398121ffd4","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":113,"text_span":"Additionally, 5.7% of patients had pathogenic germline variants identified through tumor–normal matched analysis.","confidence":0.95,"supports":true}
{"relationship_key":"canon-16adbc4d267a:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce0723b35156:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-d229f466ab51:INDICATES:C0553580","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"Histology‐specific fusion genes were identified in 32 of 80 TRS cases (40.0%) using F1CDx and in 62 of 80 TRS cases (77.5%) using GenMineTOP (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-e80979041d83:INDICATES:C0039101","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"Histology‐specific fusion genes were identified in 32 of 80 TRS cases (40.0%) using F1CDx and in 62 of 80 TRS cases (77.5%) using GenMineTOP (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-33ae5a387dcf:INDICATES:C0011634","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"Histology‐specific fusion genes were identified in 32 of 80 TRS cases (40.0%) using F1CDx and in 62 of 80 TRS cases (77.5%) using GenMineTOP (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"2058257:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"282388:TREATS:C0011634","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":239,"text_span":"In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"1148092:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":361,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of NTRK and FGFR fusions, two cases each of BRAF, RAF1, and ALK fusions, and one case each of RET, ROS1, and EGFR fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (p = 0.019).","confidence":0.95,"supports":true}
{"relationship_key":"1723476:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":361,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of NTRK and FGFR fusions, two cases each of BRAF, RAF1, and ALK fusions, and one case each of RET, ROS1, and EGFR fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (p = 0.019).","confidence":0.95,"supports":true}
{"relationship_key":"2284718:TREATS:C1261473","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":361,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of NTRK and FGFR fusions, two cases each of BRAF, RAF1, and ALK fusions, and one case each of RET, ROS1, and EGFR fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (p = 0.019).","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":113,"text_span":"BGNps exerted potent, concentration-dependent cytotoxicity in MDA-MB-231 cells, with an IC50 value of 184.3 µg/ml","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:INCREASES:C0162772","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:INCREASES:C0162772","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":73,"text_span":"BGNps trigger oxidative stress in triple-negative MDA-MB-231 cancer cells","confidence":0.9,"supports":true}
{"relationship_key":"canon-970a0d21787d:CAUSES:C0026237","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:CAUSES:C0026237","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":89,"text_span":"BGNps severely disrupt mitochondrial membrane potential in MDA-MB-231 breast cancer cells","confidence":0.9,"supports":true}
{"relationship_key":"canon-970a0d21787d:CAUSES:C0596988","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:INDUCES:C0162638","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:UPREGULATES:HGNC:11998","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:DOWNREGULATES:HGNC:990","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-970a0d21787d:DOWNREGULATES:HGNC:7458","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"C0162772:CAUSES:C0596988","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"C0162772:CAUSES:C0026237","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:PROMOTES:C0162638","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:990:INHIBITS:C0162638","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"C0812413:INDICATES:C0008031","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C0812413:INDICATES:C0032227","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C1449894:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C1449894:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":91,"text_span":"SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA)","confidence":0.95,"supports":true}
{"relationship_key":"C0069676:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C4277706:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":159,"text_span":"In the non-epithelial subpopulation, sPD-L1 levels were slightly higher, suggesting that sPD-L1 levels may be involved in the poor prognosis of PM tissue types","confidence":0.9,"supports":true}
{"relationship_key":"canon-e3ea66832515:INCREASES_RISK:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":198,"text_span":"miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor","confidence":0.95,"supports":true}
{"relationship_key":"canon-e3ea66832515:INCREASES_RISK:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":126,"text_span":"The forkhead box O1 (FOXO1) transcription factor has been identified as a target of miR-182 and miR-183 regulation in PM cells","confidence":0.95,"supports":true}
{"relationship_key":"C3657270:TREATS:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C1367202:TREATS:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C3658706:TREATS:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"canon-e3ea66832515:ASSOCIATED_WITH:canon-1d2e81a33cb5","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":126,"text_span":"The forkhead box O1 (FOXO1) transcription factor has been identified as a target of miR-182 and miR-183 regulation in PM cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-e3ea66832515:ASSOCIATED_WITH:canon-d4f44fe54274","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":198,"text_span":"miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor","confidence":0.95,"supports":true}
{"relationship_key":"C4684937:TREATS:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"C4048328:TREATS:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":263,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers","confidence":0.95,"supports":true}
{"relationship_key":"canon-64ca55581a5d:ASSOCIATED_WITH:canon-b1486a47de89","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":167,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:REGULATES:canon-6f191c8e620b","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":118,"text_span":"TSC2 functions as a tumor suppressor and is a critical negative regulator of the pro-oncogenic mTOR signaling pathway.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:23109:REGULATES:C1520113","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":151,"text_span":"The tumor suppressor gene FAT Atypical Cadherin 4 (FAT4), which regulates Wnt/β-catenin signaling, is mutated in all HCC cases in our chimpanzee study.","confidence":0.95,"supports":true}
{"relationship_key":"canon-dcbe4b366114:ASSOCIATED_WITH:canon-0276570bf1ea","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":261,"text_span":"Chimpanzee HCCs exhibited histological and immunohistochemical features similar to human tumors but displayed sharply divergent genomic landscapes. Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11110:ASSOCIATED_WITH:canon-dcbe4b366114","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:canon-dcbe4b366114","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:canon-dcbe4b366114","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3661:ASSOCIATED_WITH:canon-dcbe4b366114","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"canon-5e6d3b3286ac:INDICATES:canon-1987869ee092","document_id":"PMC11729395","section":null,"start_offset":0,"end_offset":261,"text_span":"Chimpanzee HCCs exhibited histological and immunohistochemical features similar to human tumors but displayed sharply divergent genomic landscapes. Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C2931822","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C2931822","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":127,"text_span":"The findings confirmed that the BRD7 expression level in NPC cell lines was lower compared to that in normal NPE cell line NP69","confidence":0.95,"supports":true}
{"relationship_key":"C1512554:ASSOCIATED_WITH:HGNC:1103","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":110,"text_span":"There was hypermethylation modification in BRD7 promoter, which was negatively correlated with BRD7 expression","confidence":0.95,"supports":true}
{"relationship_key":"C1512554:ASSOCIATED_WITH:HGNC:1103","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":144,"text_span":"The results of the MSP confirmed that the BRD7 promoter exhibited hypermethylation of the CpG island in NPC cell lines compared to NPE cell NP69","confidence":0.95,"supports":true}
{"relationship_key":"canon-8e794e71eb2f:TREATS:C2931822","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":246,"text_span":"we constructed a LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targeting specific methylation sites of BRD7 promoter based on five sgRNAs, and confirmed that all five sgRNA‐guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation","confidence":0.95,"supports":true}
{"relationship_key":"canon-8e794e71eb2f:TREATS:C2931822","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":234,"text_span":"the five sgRNAs‐guided dCas9‐TET1CD system could promote BRD7 expression at mRNA and protein levels in NPC cells to varying degrees when compared to the control group, of which the sgRNA2 and sgRNA5 present the most pronounced effects","confidence":0.95,"supports":true}
{"relationship_key":"canon-8e794e71eb2f:TREATS:C2931822","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":141,"text_span":"stable expression of dCas9‐TET1CD‐sgRNA2 and dCas9‐TET1CD‐sgRNA5 markedly suppressed tumour growth in vivo when compared to the control group","confidence":0.95,"supports":true}
{"relationship_key":"canon-a838ebcd9e26:ASSOCIATED_WITH:C0011901","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":246,"text_span":"we constructed a LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targeting specific methylation sites of BRD7 promoter based on five sgRNAs, and confirmed that all five sgRNA‐guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation","confidence":0.95,"supports":true}
{"relationship_key":"C0011901:INCREASES:HGNC:1103","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":234,"text_span":"the five sgRNAs‐guided dCas9‐TET1CD system could promote BRD7 expression at mRNA and protein levels in NPC cells to varying degrees when compared to the control group, of which the sgRNA2 and sgRNA5 present the most pronounced effects","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:SUBTYPE_OF:canon-15b4367a3b83","document_id":"PMC12784210","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3527:INDICATES:C0018939","document_id":"PMC11729507","section":null,"start_offset":0,"end_offset":256,"text_span":"Among different candidates, we identified the essentiality of EZH2 specifically in hematological cancer cell lines in all iMR models build on TRRUST. Interestingly, this gene has been previously identified as a drug target of different hematological tumors","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3527:ASSOCIATED_WITH:HGNC:6204","document_id":"PMC11729507","section":null,"start_offset":0,"end_offset":221,"text_span":"Here, the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3527:ASSOCIATED_WITH:HGNC:9955","document_id":"PMC11729507","section":null,"start_offset":0,"end_offset":221,"text_span":"Here, the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3071:ASSOCIATED_WITH:HGNC:4096","document_id":"PMC11729507","section":null,"start_offset":0,"end_offset":201,"text_span":"For illustration, consider the SDL interaction formed by the following two genes: {DUSP4+; GADD45B−}, where the high expression of DUSP4 and the low expression of GADD45B inhibit cellular proliferation","confidence":0.85,"supports":true}
{"relationship_key":"canon-0be605aeaa84:SUBTYPE_OF:canon-40eab9ee40f7","document_id":"PMC11729507","section":null,"start_offset":0,"end_offset":227,"text_span":"Synthetic lethality (SL) defines a type of genetic interaction where the co-occurrence of two (or more) genetic events results in cellular death, while the occurrence of either event on its own is compatible with cell viability","confidence":0.95,"supports":true}
{"relationship_key":"C4277695:ASSOCIATED_WITH:C0162772","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"C4277695:ASSOCIATED_WITH:C0023775","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"C4277695:ASSOCIATED_WITH:canon-c19e942ba01c","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":210,"text_span":"Iron in its ferrous state (Fe2+) is required for the Fenton reaction, a chemical process in which ferrous iron ions are used in the decomposition of hydrogen peroxide (H2O2) to create reactive hydroxyl radicals","confidence":0.95,"supports":true}
{"relationship_key":"canon-6e06c5d2da4d:ASSOCIATED_WITH:C0162772","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":210,"text_span":"Iron in its ferrous state (Fe2+) is required for the Fenton reaction, a chemical process in which ferrous iron ions are used in the decomposition of hydrogen peroxide (H2O2) to create reactive hydroxyl radicals","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11059:ASSOCIATED_WITH:C0017817","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":232,"text_span":"The xCT system is composed of two transmembrane proteins, SLC7A11 and SLC3A2, which create a cystine/glutamate antiporter. This allows for the uptake of cystine into the cell, which is a key precursor for glutathione (GSH) synthesis","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:INCREASES_RISK:C4277695","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.9,"supports":true}
{"relationship_key":"C3852718:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":204,"text_span":"Erastin acts through the inhibition of the xCT antiporter composed of both SLC7A11 and SLC3A2. Inhibition of this antiporter leads to decreased intracellular cystine uptake and subsequent depletion of GSH","confidence":0.95,"supports":true}
{"relationship_key":"canon-f5d8d75fc8d5:ASSOCIATED_WITH:HGNC:4555","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":102,"text_span":"RSL3 is another induction molecule that directly inhibits GPX4 by bypassing the need for GSH depletion","confidence":0.95,"supports":true}
{"relationship_key":"681479:TREATS:C2239176","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":227,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction. An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"681479:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":227,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction. An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"C4277695:ASSOCIATED_WITH:C0011306","document_id":"PMC_FERROPTOSIS_2024","section":null,"start_offset":0,"end_offset":133,"text_span":"Dendritic cells failed to effectively present tumor antigens as they undergo ferroptosis, resulting in weakened CD8+ T cell responses","confidence":0.85,"supports":true}
{"relationship_key":"C0242275:INCREASES_EXPRESSION_OF:HGNC:11191","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":95,"text_span":"EGF supplement significantly upregulates both the protein and mRNA expression of the Sox11 gene","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3236:DECREASES_EXPRESSION_OF:HGNC:11191","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":64,"text_span":"EGFR inhibitor suppresses the expression of SOX11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11364:REGULATES:HGNC:11191","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":111,"text_span":"STAT3 bound to the Sox11 gene promoter and transcriptionally upregulated the expression of Sox11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:C1523298","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:C1523298","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:DECREASES_EXPRESSION_OF:C0042172","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:C0068408","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:C0042666","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:C0016055","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:REGULATES:HGNC:12428","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":68,"text_span":"SOX11 bound to the promoter region of the Twist1 gene in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:REGULATES:HGNC:12428","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":64,"text_span":"SOX11 promotes tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12428","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:20670","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:11128","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:11129","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:11642","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:14881","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:C0178874","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":64,"text_span":"SOX11 promotes tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:ASSOCIATED_WITH:C1168401","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":95,"text_span":"EGF supplement significantly upregulates both the protein and mRNA expression of the Sox11 gene","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:ASSOCIATED_WITH:C1168401","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":64,"text_span":"EGFR inhibitor suppresses the expression of SOX11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:ASSOCIATED_WITH:C1168401","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":111,"text_span":"STAT3 bound to the Sox11 gene promoter and transcriptionally upregulated the expression of Sox11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:INCREASES_RISK:C2239176","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:REGULATES:HGNC:9077","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":111,"text_span":"AURKA directly phosphorylates the Thr210 residue within the PLK1 kinase domain, initiating mitotic progression.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11393:REGULATES:HGNC:11998","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":199,"text_span":"Overexpression of AURKA has been shown to destabilize p53 through Ser315 phosphorylation, leading to loss of function, centrosome amplification, chromosomal instability, and oncogenic transformation.","confidence":0.9,"supports":true}
{"relationship_key":"canon-9c7abebc4ce2:INDICATES:C0019204","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":241,"text_span":"Phospho-P53Ser315 levels were significantly higher in both HBV-HCC and Cr-HCC groups compared to the control group (p = 0.002 and p < 0.001, respectively). Cr-HCC cases also showed significantly higher levels compared to HBV-HCC (p = 0.025).","confidence":0.95,"supports":true}
{"relationship_key":"canon-9c7abebc4ce2:INDICATES:C0019204","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":241,"text_span":"Phospho-P53Ser315 levels were significantly higher in both HBV-HCC and Cr-HCC groups compared to the control group (p = 0.002 and p < 0.001, respectively). Cr-HCC cases also showed significantly higher levels compared to HBV-HCC (p = 0.025).","confidence":0.95,"supports":true}
{"relationship_key":"canon-e3f19beb9ea5:INDICATES:C0019204","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":141,"text_span":"For phospho-PLK1Thr210, Cr-HCC cases showed statistically higher expression compared to both the control group and HBV-HCC cases (p = 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C2239176","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":118,"text_span":"experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models.","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:11393:CAUSES:C0919532","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":199,"text_span":"Overexpression of AURKA has been shown to destabilize p53 through Ser315 phosphorylation, leading to loss of function, centrosome amplification, chromosomal instability, and oncogenic transformation.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11393:REGULATES:C1516334","document_id":"extracted_paper_1","section":null,"start_offset":0,"end_offset":111,"text_span":"AURKA directly phosphorylates the Thr210 residue within the PLK1 kinase domain, initiating mitotic progression.","confidence":0.9,"supports":true}
{"relationship_key":"canon-09b6502af7a5:INDICATES:C0085390","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":120,"text_span":"When TP53 PVs/LPVs are identified in a comprehensive germline panel, this raises concern for Li–Fraumeni syndrome (LFS).","confidence":0.95,"supports":true}
{"relationship_key":"canon-09b6502af7a5:INDICATES:C0085390","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":132,"text_span":"The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient and is diagnostic for LFS.","confidence":0.95,"supports":true}
{"relationship_key":"canon-b080a8df4cb0:TREATS:C0007124","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":152,"text_span":"She completed a comprehensive 76‐gene germline genetic test, which revealed tumor protein p53 (TP53) likely pathogenic variant (LPV; c.716A>G; p.N239S).","confidence":0.95,"supports":true}
{"relationship_key":"canon-b080a8df4cb0:TREATS:canon-fbec289eee77","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":152,"text_span":"She completed a comprehensive 76‐gene germline genetic test, which revealed tumor protein p53 (TP53) likely pathogenic variant (LPV; c.716A>G; p.N239S).","confidence":0.95,"supports":true}
{"relationship_key":"canon-09b6502af7a5:ASSOCIATED_WITH:canon-a12e1b3e9548","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":132,"text_span":"The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient and is diagnostic for LFS.","confidence":0.95,"supports":true}
{"relationship_key":"canon-54c44ed244b7:INDICATES:C0085390","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":132,"text_span":"The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient and is diagnostic for LFS.","confidence":0.95,"supports":true}
{"relationship_key":"C0206672:ASSOCIATED_WITH:canon-09b6502af7a5","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":81,"text_span":"The same specific TP53 LPV (c.716A>G [p.N239S]) was detected in all three tumors.","confidence":0.95,"supports":true}
{"relationship_key":"canon-85c393d4e358:INDICATES:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ef82e593f42:INDICATES:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-701945485364:INDICATES:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-13e4a072a474:INDICATES:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-df1bf70a5d78:INDICATES:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":196,"text_span":"We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f4e0962db5df:TREATS:C0221406","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":196,"text_span":"We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-6cbdab1916ec:ASSOCIATED_WITH:C0282488","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":158,"text_span":"Cross-sensitization in the pelvis may contribute to etiology of functional pelvic pain disorders such as interstitial cystitis/bladder pain syndrome (IC/BPS).","confidence":0.9,"supports":true}
{"relationship_key":"C1565686:ASSOCIATED_WITH:C0021368","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":204,"text_span":"Increasing evidence suggests the involvement of transient receptor potential vanilloid 1 (TRPV1) receptors in the development of neurogenic inflammation in the pelvis and pelvic organ cross-sensitization.","confidence":0.9,"supports":true}
{"relationship_key":"C1565686:ASSOCIATED_WITH:canon-6cbdab1916ec","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":204,"text_span":"Increasing evidence suggests the involvement of transient receptor potential vanilloid 1 (TRPV1) receptors in the development of neurogenic inflammation in the pelvis and pelvic organ cross-sensitization.","confidence":0.9,"supports":true}
{"relationship_key":"C0073379:TREATS:canon-7ba0f30c87f0","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":249,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05).","confidence":0.95,"supports":true}
{"relationship_key":"C0073379:TREATS:canon-7ba0f30c87f0","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":241,"text_span":"The duration of long-lasting excitatory responses, but not short-lasting responses of bladder spinal neurons during acute colitis was significantly reduced by RTX from 52.9±6.6 s (n=21, vehicle group) to 34.4±2.1 s (RTX group, n=21, p≤0.05).","confidence":0.95,"supports":true}
{"relationship_key":"C0073379:ASSOCIATED_WITH:canon-b12bd17f4ad0","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":196,"text_span":"However, activation of TRPV1 receptors in the urinary bladder prior to acute colitis increased the number of bladder neurons receiving input from large somatic fields from 22.7% to 58.2% (p≤0.01).","confidence":0.95,"supports":true}
{"relationship_key":"C0073379:ASSOCIATED_WITH:C1565686","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":220,"text_span":"We detected a significant decrease in TRPV1 protein in the urothelium after intravesical treatment with RTX which was previously shown by other groups and was linked to long lasting reduction in bladder pain and urgency.","confidence":0.9,"supports":true}
{"relationship_key":"C0009319:ASSOCIATED_WITH:canon-6cbdab1916ec","document_id":"PMC3462445","section":null,"start_offset":0,"end_offset":172,"text_span":"The results of our study provide evidence that intravesical RTX reduces the effects of viscerovisceral cross-talk induced by colonic inflammation on bladder spinal neurons.","confidence":0.9,"supports":true}
{"relationship_key":"canon-47ca79ff88ff:INCREASES_RISK:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":162,"text_span":"Amyloid-β oligomers trigger Alzheimer disease pathophysiology via the interaction of cellular prion protein (PrPC) with metabotropic glutamate receptor 5 (mGluR5)","confidence":0.95,"supports":true}
{"relationship_key":"C0033684:ASSOCIATED_WITH:C0389958","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":162,"text_span":"Amyloid-β oligomers trigger Alzheimer disease pathophysiology via the interaction of cellular prion protein (PrPC) with metabotropic glutamate receptor 5 (mGluR5)","confidence":0.95,"supports":true}
{"relationship_key":"canon-66f112cdbae8:ASSOCIATED_WITH:C0389958","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":85,"text_span":"PrPC region 91–153 interacts preferentially with the activated conformation of mGluR5","confidence":0.95,"supports":true}
{"relationship_key":"canon-7e28cbba9bb2:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"canon-7e28cbba9bb2:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"C0243192:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"C0243192:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"C0243076:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"C0243076:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.95,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0032000","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":187,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality.","confidence":0.95,"supports":true}
{"relationship_key":"C0032000:INCREASES_RISK:C0020621","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":187,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality.","confidence":0.95,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C1563740","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":179,"text_span":"This may be related to persistence of visceral adiposity, adverse adipokine profile, glucose intolerance, hypertension, dyslipidemia, atherosclerosis and a procoagulant phenotype.","confidence":0.85,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C1861172","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":163,"text_span":"In a multicenter retrospective cohort study of 473 CS patients (360 CD), the incidence of VTE before treatment of hypercortisolemia was 14.6 per 1000 persons/year.","confidence":0.95,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0271650","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":109,"text_span":"The prevalence of overt diabetes mellitus is 20–47 % and that of impaired glucose tolerance is 21–64 % in CD.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C0080179","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":193,"text_span":"The prevalence of fractures and osteoporosis as assessed by dual energy X-ray absorptiometry (DXA) has been reported to be 15–50 and 38–50 % respectively, and may be a presenting feature of CD.","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:ASSOCIATED_WITH:C4551538","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":113,"text_span":"Hippocampal atrophy was seen in 27 % of 12 active CS patients and correlated with performance on cognitive tests.","confidence":0.9,"supports":true}
{"relationship_key":"C0087111:TREATS:C0221406","document_id":"PMC_CUSHING_COMORBIDITIES","section":null,"start_offset":0,"end_offset":187,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality.","confidence":0.95,"supports":true}
{"relationship_key":"C0081786:ASSOCIATED_WITH:C0948780","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":261,"text_span":"examples being oral biofilms ('dental plaque') and biofilms involved in a variety of pathological conditions like for instance osteomyelitis, chronic otitis media, the infected diabetic foot, chronic bacterial prostatitis or in biomaterial-associated infections","confidence":0.9,"supports":true}
{"relationship_key":"canon-4518298f73a6:ASSOCIATED_WITH:canon-47ec3f94376b","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":162,"text_span":"Penetration of chlorhexidine into oral biofilms increased with increasing relative importance of the slow and decreasing importance of the fast relaxation element","confidence":0.9,"supports":true}
{"relationship_key":"C0008196:TREATS:C0081786","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":162,"text_span":"Penetration of chlorhexidine into oral biofilms increased with increasing relative importance of the slow and decreasing importance of the fast relaxation element","confidence":0.9,"supports":true}
{"relationship_key":"C0017436:TREATS:C0033809","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":156,"text_span":"Gentamicin has been shown to have enhanced killing in P. aeruginosa and Escherichia coli biofilms in vitro and in vivo in rabbits after ultrasound treatment","confidence":0.9,"supports":true}
{"relationship_key":"C0017436:TREATS:C0014834","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":156,"text_span":"Gentamicin has been shown to have enhanced killing in P. aeruginosa and Escherichia coli biofilms in vitro and in vivo in rabbits after ultrasound treatment","confidence":0.9,"supports":true}
{"relationship_key":"canon-48ba1fd13786:INCREASES:C0017436","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":156,"text_span":"Gentamicin has been shown to have enhanced killing in P. aeruginosa and Escherichia coli biofilms in vitro and in vivo in rabbits after ultrasound treatment","confidence":0.9,"supports":true}
{"relationship_key":"C0001047:AFFECTS:C0033809","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":169,"text_span":"Pseudomonas aeruginosa biofilms on stainless steel were affected by N-acetyl-L-cysteine, as both the fast and intermediate Maxwell elements were reduced by more than 50%","confidence":0.9,"supports":true}
{"relationship_key":"canon-4518298f73a6:ASSOCIATED_WITH:canon-6599e74962be","document_id":"PMC_UNKNOWN","section":null,"start_offset":0,"end_offset":162,"text_span":"Penetration of chlorhexidine into oral biofilms increased with increasing relative importance of the slow and decreasing importance of the fast relaxation element","confidence":0.9,"supports":true}
{"relationship_key":"C1831808:TREATS:C0004238","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:TREATS:C0004238","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":281,"text_span":"We performed a cost-effectiveness analysis of apixaban versus warfarin in non-valvular atrial fibrillation (NVAF) in patients suitable for oral anticoagulation in Argentina. A Markov-based model including both costs and effects were used to simulate a cohort of patients with NVAF.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:C0013922","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:C0013922","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:canon-8cada800d94c","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:REDUCES_RISK:canon-8cada800d94c","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":280,"text_span":"In a VKA suitable cohort of 1000 patients with NVAF, compared with warfarin, the use of apixaban resulted in 24 fewer strokes (including first and recurrent ischemic and hemorrhagic) or systemic embolism, 41 fewer major bleeding events, and 26 fewer cardiovascular-related deaths.","confidence":0.95,"supports":true}
{"relationship_key":"C1831808:MORE_COST_EFFECTIVE_THAN:C0043031","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":260,"text_span":"The study revealed that apixaban is cost-effective compared with warfarin using a willingness to pay threshold ranging from 1 to 3 per capita Gross Domestic Product (11558 – 34664 USD) with an incremental cost-effectiveness ratio of 786.08 USD per QALY gained.","confidence":0.95,"supports":true}
{"relationship_key":"C3178753:INDICATES:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"C3178754:INDICATES:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"canon-096dc25034a4:DEMONSTRATES_EFFICACY:C1831808","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"canon-d841f2e34caa:DEMONSTRATES_EFFICACY:C1831808","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"canon-66f254b49229:INDICATES:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":115,"text_span":"We recommend a short corticotropin test (250 μg) as the 'gold standard' diagnostic tool to establish the diagnosis.","confidence":0.95,"supports":true}
{"relationship_key":"canon-8316fb4163d9:INDICATES:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":183,"text_span":"If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels.","confidence":0.95,"supports":true}
{"relationship_key":"canon-1f0e6343b3dd:INDICATES:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":183,"text_span":"If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels.","confidence":0.95,"supports":true}
{"relationship_key":"4316:TREATS:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"5492:TREATS:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"5492:TREATS:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":56,"text_span":"In children, hydrocortisone (∼8 mg/m2/d) is recommended.","confidence":0.95,"supports":true}
{"relationship_key":"C0027497:ASSOCIATED_WITH:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"C0015672:ASSOCIATED_WITH:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"C0020649:ASSOCIATED_WITH:C0001623","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"canon-6c5d3c71771f:CAUSES:C0030552","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":199,"text_span":"Hemi-sectioned spinal cord injury (hSCI) can lead to spastic paralysis on the injured side, as well as flaccid paralysis on the contralateral side, which can negatively affect a patient's daily life.","confidence":0.95,"supports":true}
{"relationship_key":"canon-6c5d3c71771f:CAUSES:C0030552","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":199,"text_span":"Hemi-sectioned spinal cord injury (hSCI) can lead to spastic paralysis on the injured side, as well as flaccid paralysis on the contralateral side, which can negatively affect a patient's daily life.","confidence":0.95,"supports":true}
{"relationship_key":"canon-9224c13c92ba:ASSOCIATED_WITH:canon-ab5942b7afda","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":226,"text_span":"A 19-year-old woman was scheduled to undergo bilateral sagittal split ramus osteotomy after being diagnosed with a jaw deformity. Preoperative electrocardiography (ECG) revealed a junctional rhythm with a slow heart rate (HR).","confidence":0.95,"supports":true}
{"relationship_key":"6387:ASSOCIATED_WITH:C0002921","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":196,"text_span":"At 90 minutes after anesthesia induction, local anesthesia with 10 mL of 1% lidocaine and 1:100,000 adrenaline was administered. A junctional rhythm appeared 15 minutes after the local anesthesia.","confidence":0.95,"supports":true}
{"relationship_key":"C0002921:INCREASES_RISK:canon-9224c13c92ba","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":196,"text_span":"At 90 minutes after anesthesia induction, local anesthesia with 10 mL of 1% lidocaine and 1:100,000 adrenaline was administered. A junctional rhythm appeared 15 minutes after the local anesthesia.","confidence":0.95,"supports":true}
{"relationship_key":"C0039044:INCREASES_RISK:canon-9224c13c92ba","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":139,"text_span":"We believe that the atrioventricular nodal pacemaker cells accelerated because of the increased sympathetic activity due to the adrenaline.","confidence":0.9,"supports":true}
{"relationship_key":"canon-2b3f7b975eeb:ASSOCIATED_WITH:canon-bcc5eec8e71a","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":131,"text_span":"On the preoperative ECG, the junctional rhythm with slow HR appeared as an escaped beat caused by slowing of the primary pacemaker.","confidence":0.9,"supports":true}
{"relationship_key":"canon-bcc5eec8e71a:SUBTYPE_OF:canon-9224c13c92ba","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":131,"text_span":"On the preoperative ECG, the junctional rhythm with slow HR appeared as an escaped beat caused by slowing of the primary pacemaker.","confidence":0.9,"supports":true}
{"relationship_key":"C0394648:TREATS:C0027073","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":224,"text_span":"A reduction in the size of hypoesthetic area with TPI was observed in 27 (58.7%) patients. All the 27 patients experienced a reduction in pain intensity by more than 50% in a numerical rating scale score through TPI therapy.","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0027073","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":111,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy","confidence":0.95,"supports":true}
{"relationship_key":"C0027073:ASSOCIATED_WITH:C0020580","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":67,"text_span":"Thirty-four (74%) of 46 patients with MTrP had tactile hypoesthesia","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0020580","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":224,"text_span":"A reduction in the size of hypoesthetic area with TPI was observed in 27 (58.7%) patients. All the 27 patients experienced a reduction in pain intensity by more than 50% in a numerical rating scale score through TPI therapy.","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0020580","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":200,"text_span":"In all these 27 patients, a reduction in the size of the hypoesthetic area was observed during the course of treatment, with a complete disappearance of the tactile hypoesthesia observed in 6 patients","confidence":0.95,"supports":true}
{"relationship_key":"C0023660:TREATS:C0458343","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":111,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy","confidence":0.95,"supports":true}
{"relationship_key":"C0040864:TREATS:C0458343","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":111,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy","confidence":0.95,"supports":true}
{"relationship_key":"C0458343:ASSOCIATED_WITH:canon-ca27ea41b74f","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":190,"text_span":"Such inhibition of neuronal activity in the somatosensory cortex induced by ongoing afferent nociceptive input from MTrP may underlie the reversible tactile hypoesthesia in patients with MPS","confidence":0.85,"supports":true}
{"relationship_key":"C0028420:TREATS:C0027073","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":111,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy","confidence":0.95,"supports":true}
